文档介绍:Type of Infection Dose Every 24 Duration
HIGHLIGHTS OF PRESCRIBING INFORMATION
hours (days)
These highlights do not include all the information needed to use
®
LEVAQUIN safely and effectively. See full prescribing information Inhalational Anthrax (Post-Exposure) ()
for LEVAQUIN ®.
LEVAQUIN® (levofloxacin) Tablet, Film Coated for Oral use Adults and Pediatric Patients > 50 kg 500 mg 60
LEVAQUIN® (levofloxacin) Solution for Oral use 8 mg/kg BID
Pediatric Patients < 50 kg and ≥ 6 months of
LEVAQUIN® (levofloxacin) Injection, Solution, Concentrate for (not to exceed 60
age
Intravenous use 250 mg/dose)
LEVAQUIN® (levofloxacin) Injection, Solution for Intravenous use
Initial . Approval: 1996 Plague ()
WARNING: Adults and Pediatric Patients > 50 kg 500 mg 10 to 14
See full prescribing information plete boxed warning. 8 mg/kg BID
® Pediatric Patients < 50 kg and ≥ 6 months of
Fluoroquinolones, including LEVAQUIN , are associated with an (not to exceed 10 to 14
age
increased risk of tendinitis and tendon rupture in all ages. This risk is 250 mg/dose)
further increased in older patients usually over 60 years of age, in • Adjust dose for creatinine clearance < 50 mL/min (, , )
patients taking corticosteroid drugs, and in patients with kidney, heart or • IV Injection, Single-Use or Premix: Slow IV infusion only, over
lung transplants [See Warnings and Precautions ()]. 60 or 90 minutes depending on dose. Avoid rapid or bolus IV ()
Fluoroquinolones, including LEVAQUIN®, may exacerbate muscle
• Dilute single-use vials to 5 mg/mL prior to IV infusion ()
weakness in persons with myasthenia gravis. Avoid LEVAQUIN® in
• Do not mix with other medications in vial or IV line ()
patients with a known history of myasthenia gravis [See Warnings and
Precautions ()].
To reduce the development of drug-resistant bacteria and maintain the ———————DOSAGE FORMS AND STR